UNSPSC 51341603: Rimantadine

This classification denotes an antiviral agent with the molecular formula C12H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0T2EF4JQTU, chemically known as 1-adamantanemethylamine, .alpha.-methyl-, hydrochloride but generally known as rimantadine, which bears US NIH Compound Identifier 5071. European Medicines Agency schedules Rimantadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10320MIG.

UNSPSC 51341603 Rimantadine is a Commodity code that nominally covers a single antiviral pharmaceutical product, but recent state and local solicitations tagged with this code show little activity directly matching its scope. The four recent opportunities in the block span naloxone and drug deactivation systems procurement (Seminole County, Florida), a therapeutic pharmacy initiative RFI for direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies for emergency response (City of Tampa Fire Department), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). None of these solicitations explicitly target rimantadine or antiviral medications as a primary commodity. The issuing bodies represent a mixed jurisdiction base—county health departments, state HHS agencies, municipal fire departments, and state cooperative purchasing alliances—but the opportunities do not cohere around a single product category or consistent procurement pattern aligned with the rimantadine code's nominal scope.

Activity under this code appears fragmented and geographically dispersed. Recent solicitations span Florida, Texas, Minnesota, and Oregon, but the mismatch between the code designation and the actual goods being procured suggests that state and local procurement systems may be applying this code inconsistently or to broader pharmaceutical acquisition activity rather than rimantadine specifically. The Seminole County naloxone procurement (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually; the City of Tampa medical and first aid supplies bid (26P00145, due March 13, 2026, estimated at $700,000.00) targeted emergency response consumables for the Fire Department; the Texas HHS RFI (HHS0017013, posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription fulfillment; and the MMCAP RFP (S1070000015802, due March 26, 2026) pursued generic pharmaceuticals and OTC products through three authorized wholesalers. The code shows limited recent procurement activity that directly aligns with rimantadine as a distinct pharmaceutical commodity.